EFPIA

Key TakeawaysEurope's pharmaceutical productivity outpaces the general economy in all studied member states. The growing R&D investment gap requires immediate strategic action to...

Key TakeawaysEmbrace diverse evidence synthesis techniques to enhance the quality of JCA dossiers. Recognize the importance of ITCs in addressing gaps left by...

Key TakeawaysEFPIA raises concerns that the Urban Wastewater Treatment Directive could harm the competitiveness of Europe's pharmaceutical sector and disrupt the supply of...

Key TakeawaysBalancing privacy and research progress is crucial when reusing health data. The EFPIA's Anonymisation Gradient offers a framework to understand privacy and...

Key TakeawaysThe pharmaceutical industry's data disclosure efforts are increasing, but the impact on public health remains uncertain. EFPIA is prioritizing investments in disclosure...

Implementing cancer screening programmes in the EU has proven to be a vital step in improving survival rates, quality of life, and reducing treatment...

The European Federation of Pharmaceutical Industries and Associations (EFPIA) acknowledges the final agreement on the European Health Data Space (EHDS) Regulation as a pivotal...

The EU-X-CT Cross-Border Clinical Trials Initiative, co-led by the European Forum for Good Clinical Practice (EFGCP) and the European Federation of Pharmaceutical Industries and...

In shaping the next European Framework Programme for Research and Innovation (FP10), 110 European associations representing key RD&I stakeholders urge EU Institutions to significantly...

The European Union (EU) faces a crucial opportunity to address cardiovascular disease (CVD) while enhancing competitiveness in the life sciences sector. The High-Level Conference...

At this critical moment of political change in Europe, EFPIA is asking EU leaders to collaborate with the industry to create opportunities for the...

New data from the European Federation of Pharmaceutical Industries and Associations (EFPIA) reveals multiple factors leading to unequal medicine access across Europe. On average,...

New data demonstrates the value of regulatory data protection (RDP) and its impact on European competitiveness and patient access to medicines. The European Federation...

Pharmaceutical trade associations have applauded the World Health Organization (WHO) for recognizing the European Medicines Regulatory Network (EMRN) and the United States Food and...

Across Europe, while most countries utilize health technology assessment (HTA) to evaluate the clinical and economic evidence of medications for reimbursement through public healthcare...